Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic acarbose-feeding increases GLUT1 protein without changing intestinal glucose absorption function.

Leonardo Paiva1, Ralf Binsack, Ubiratan Fabres Machado

  • 1Department of Physiology and Biophysics, University of São Paulo, Av. Prof. Lineu Prestes 1524, 05508-900, São Paulo, Brazil.

European Journal of Pharmacology
|January 10, 2002
PubMed
Summary

The antidiabetic drug acarbose, an alpha-glucosidase inhibitor, does not affect intestinal glucose absorption. Chronic acarbose use in rats did not alter glucose transporter gene expression or overall glucose absorption.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biphasic <i>Slc2a4</i> Gene Expression in 3T3-L1 Adipocytes in Response to Treatment with Low and High Concentrations of Daidzein and Genistein.

Current issues in molecular biology·2025
Same author

Aerobic Exercise Training Protects Against Insulin Resistance, Despite Low-Sodium Diet-Induced Increased Inflammation and Visceral Adiposity.

International journal of molecular sciences·2024
Same author

Nuclear Factor-Kappa-B Mediates the Advanced Glycation End Product-Induced Repression of <i>Slc2a4</i> Gene Expression in 3T3-L1 Adipocytes.

International journal of molecular sciences·2024
Same author

The Prolonged Activation of the p65 Subunit of the NF-Kappa-B Nuclear Factor Sustains the Persistent Effect of Advanced Glycation End Products on Inflammatory Sensitization in Macrophages.

International journal of molecular sciences·2024
Same author

Glucose Transport and Utilization in the Hippocampus: From Neurophysiology to Diabetes-Related Development of Dementia.

International journal of molecular sciences·2023
Same author

Postmortem Brains from Subjects with Diabetes Mellitus Display Reduced GLUT4 Expression and Soma Area in Hippocampal Neurons: Potential Involvement of Inflammation.

Cells·2023

Area of Science:

  • Pharmacology
  • Gastroenterology
  • Endocrinology

Background:

  • Acarbose is an alpha-glucosidase inhibitor used to manage type 2 diabetes by reducing postprandial glucose.
  • Its effects on intestinal glucose transporter expression (SGLT1, GLUT1, GLUT2) remain largely uncharacterized.

Purpose of the Study:

  • To investigate the impact of chronic acarbose administration on the expression of intestinal glucose transporters SGLT1, GLUT1, and GLUT2.
  • To determine if acarbose influences intestinal glucose absorption.

Main Methods:

  • Wistar rats were fed a standard diet with or without acarbose (40 mg/100 g chow) for 40 days.
  • Gene expression of SGLT1, GLUT1, and GLUT2 was analyzed in the small intestine.
  • Intestinal glucose absorption was assessed via an ex vivo perfusion study.

Related Experiment Videos

Main Results:

  • Acarbose treatment did not alter SGLT1 and GLUT2 gene expression in the small intestine.
  • GLUT1 protein levels increased by 75% in the middle small intestine of acarbose-treated rats.
  • Despite changes in GLUT1 protein, overall intestinal glucose absorption remained unaffected.

Conclusions:

  • Chronic acarbose administration does not significantly alter intestinal glucose transporter gene expression or glucose absorption capacity.
  • The observed increase in GLUT1 protein in the middle small intestine did not translate to functional changes in glucose uptake.